Plain-English translation of NCT06679829 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a drug that blocks inflammation, works better when combined with (a chemotherapy drug) during stem cell transplant treatment for multiple myeloma. The study will compare this new combination approach to the standard treatment currently used, and will measure whether the medication helps reduce side effects and works as well or better than the usual approach.
Doctors want to find ways to make stem cell transplants safer and more effective for older patients with multiple myeloma. This medication targets inflammation in the body, which may help reduce severe side effects that patients sometimes experience after transplant.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive injections of the medication called about a week before and two weeks after your stem cell transplant. You will also receive chemotherapy () on specific days before your transplant. The research team will take small blood samples several times after your chemotherapy to check how your body is processing the drug, and they will use this information to adjust your dosing. You will be monitored closely during and after your transplant as part of standard care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States